SeizuresPhase 3NCT00319501
Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.
A Phase 3 study testing Vanquix Auto-Injector (Diazepam Injection) in people with Seizures and Epilepsies, Partial, run by Pfizer at 86 sites in United States.
Trial summary
To evaluate the efficacy and safety of diazepam in the management of refractory epilepsy in selected patients who require intermittent medical intervention for the control of episodes of acute repetitive seizures. Read more about this study
- Who is it for?
- Ages 2 years and older
- Conditions the study is for
- Seizures, Epilepsies, Partial, Epilepsy, Complex Partial
- What is being tested?
- Vanquix Auto-Injector (Diazepam Injection)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 234 participants
- Where
- 86 sitesUnited States
- Study dates
- Jan 2006to Jul 2014
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- For Patient:
- Older than 2 years of age and between 6 and 136 kg body weight
- Recipient of clinical diagnosis of epilepsy, taking a stable antiepileptic drug regimen for at least 2 weeks, and requiring intermittent medical intervention to control episodes of acute repetitive seizures (ARS)
- Experienced at least 2 episodes of ARS in previous year, one of which occurred in previous 6 months
- Has episodes of ARS that include complex partial or generalized seizures
- Has a responsible caregiver available to participate
Show all 14Show fewer
- Is not pregnant or lactating and is practicing an acceptable method of birth control.
- For Caregiver:
- Age of 18 years or older and has demonstrated responsibility as a caregiver through training to:
- Recognize an episode of repetitive seizures for which the injection was intended,
- Administer study drug
- Count and record seizures and respiratory rate in the patient diary,
- Monitor the patient and record observations in the patient diary for 12 hours following study drug treatment
- Recognize the need for immediate medical attention.
Who cannot join
- For Patient:
- Petit mal status or petit mal variant status
- History of ARS consistently progressing to status epilepticus
- History of failure to respond to benzodiazepine treatment
- Hypersensitivity to diazepam
- Acute narrow angle glaucoma
Show all 9Show fewer
- Alcohol and/or other substance abuse
- Has taken another investigational drug in previous 30 days
- Acute or progressive neurologic or severe psychiatric disease or severe mental abnormality.
Trial locations and contacts
86 sites in 1 country.
86 sites in 1 country
United States86 sites
Child Neurology Associates, PC
Atlanta, Georgia, 30342
Consultants in Epilepsy and Neurology, PLLC
Boise, Idaho, 83702
Bradenton Research Center, Inc.
Bradenton, Florida, 34205
Elmwood Clinic
Buffalo, New York, 14207
Millard Fillmore Gates Hospital/Comprehensive Epilepsy Center
Buffalo, New York, 14209
Women and Children's Hospital of Buffalo
Buffalo, New York, 14222
Lahey Clinic Medical Center
Burlington, Massachusetts, 01805
Medical University of South Carolina Hospitals and Clinics
Charleston, South Carolina, 29425
Medical University of South Carolina/Department of Pharmacy Service
Charleston, South Carolina, 29425
Medical University of South Carolina
Charleston, South Carolina, 29425
The Comprehensive Epilepsy Care Center For Children and Adults
Chesterfield, Missouri, 63017
Comer Children's Hospital
Chicago, Illinois, 60637
University of Chicago Hospital Pharmacy
Chicago, Illinois, 60637
University of Chicago Medical Center (UCMC) Center for Advanced Medicine (CAM)
Chicago, Illinois, 60637
University of Chicago Medical Center (UCMC)
Chicago, Illinois, 60637
Morton Plant Hospital Epilepsy Clinic
Clearwater, Florida, 33756
Morton Plant Hospital Pharmacy
Clearwater, Florida, 33756
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195-5102
The Cleveland Clinic Health Systems
Cleveland, Ohio, 44195-5102
Ohio State University Neurology Clinic
Columbus, Ohio, 43210
Ohio State University University Hospital
Columbus, Ohio, 43210
Ohio State University
Columbus, Ohio, 43210
Neurological Clinic of Texas, PA
Dallas, Texas, 75230
Cook Children's Medical Center Office of Grants and Research
Fort Worth, Texas, 76104
Cook Children's Medical Center
Fort Worth, Texas, 76104
Cook Children's Physcian Network
Fort Worth, Texas, 76104
Mid-South Physicians Group, PLLC
Germantown, Tennessee, 38138
Clinical Research Center of New Jersey
Gibbsboro, New Jersey, 08026
Cone Health Child Neurology
Greensboro, North Carolina, 27401
Guilford Neurologic Associates
Greensboro, North Carolina, 27405
Child Neurology Center of NorthWest Florida
Gulf Breeze, Florida, 32561
NorthWest Florida Clinical Research Group, LLC
Gulf Breeze, Florida, 32561
Stein Life Child Neurology Medical Specialists Inc.
Irvine, California, 92606
MRI Location
Kansas City, Missouri, 64111
St Luke's Hospital Neurological Consultants
Kansas City, Missouri, 64111
St Luke's Hospital
Kansas City, Missouri, 64111
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Emery Neuroscience Center
Lighthouse PT, Florida, 33064
Clinical Trials, Inc
Little Rock, Arkansas, 72205
Collaborative NeuroScience Network, LLC
Long Beach, California, 90806
University Neurologists PSC Pediatric Division
Louisville, Kentucky, 40202
University of Louisville Ambulatory Care Building Clinic
Louisville, Kentucky, 40202
University of Louisville Clinical Trials Unit
Louisville, Kentucky, 40202
Pediatric Neurology and Epilepsy Center
Loxahatchee Groves, Florida, 33470
University of Tennessee Lebonheur Pediatric Specialists Inc.
Memphis, Tennessee, 38103
Miami Children's Hospital
Miami, Florida, 33155
Access Clinical Trial, Inc.
Nashville, Tennessee, 37203
CMC - Physician's Park
Nashville, Tennessee, 37203
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-2551
Vanderbilt Epilepsy Clinic
Nashville, Tennessee, 37232
Vanderbilt University Hospital Pharmacy
Nashville, Tennessee, 37232
University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical Group
New Brunswick, New Jersey, 08901
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08901
NYU Medical Center, Comprehensive Epilepsy Center
New York, New York, 10016
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92658
Brain and Spine Surgeons of Orange County
Newport Beach, California, 92663
Neurology Clinic, PC
Northport, Alabama, 35476
The Neurology and Pain Clinic
Orangeburg, South Carolina, 29118
EKG only
Orlando, Florida, 32806
Pediatric Neurology, PA
Orlando, Florida, 32819
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania, 19134-1095
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania, 19134
North Pacific Epilepsy Research/The Northrup Center
Portland, Oregon, 97210
Raleigh Neurology Associates, PA
Raleigh, North Carolina, 27607
Virginia Commonwealth University Health System
Richmond, Virginia, 23298-0042
Virginia Commonwealth University Division of Child Neurology
Richmond, Virginia, 23298-0211
Virginia Commonwealth University Ambulatory Care Center/Department of Neurology
Richmond, Virginia, 23298-0599
Strong Memorial Hospital
Rochester, New York, 14642
University of Rochester, Strong Epilepsy Center
Rochester, New York, 14642
Drug Shipment
Sacramento, California, 95816
Sacramento Comprehensive Epilepsy Program
Sacramento, California, 95816
Sutter Cancer Center Specialty Clinic
Sacramento, California, 95816
Sutter Institute for Medical Research
Sacramento, California, 95816
Northern California Cardiology
Sacramento, California, 95819
Neurology Clinic of St Cloud
Saint Cloud, Minnesota, 56303
Alamo City Clinical Research, LLC
San Antonio, Texas, 78258
Savannah Neurology, PC
Savannah, Georgia, 31405
Harborview Medical Center
Seattle, Washington, 98104
University of Washington Regional Epilepsy Center, Harborview Medical Center
Seattle, Washington, 98104
AMO Corp
Tallahassee, Florida, 32308
Tallahassee Neurological Clinic
Tallahassee, Florida, 32308
Pediatric Epilepsy & Neurology Specialists
Tampa, Florida, 33609
Willsey Research Inc
Tampa, Florida, 33613
Wellspan Neurosciences
York, Pennsylvania, 17402
Apple Hill Medical Center (EKG & Lab Draw)
York, Pennsylvania, 17403
About this study
Official title: A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures
To evaluate the efficacy and safety of diazepam in the management of refractory epilepsy in selected patients who require intermittent medical intervention for the control of episodes of acute repetitive seizures. In addition, to assess the support provided by caregivers who are not themselves or not under the direct supervision of health care professionals at the time of administration.
- Being tested
- Placebo, Vanquix Auto-Injector (Diazepam Injection)
- Keywords
- Acute Repetitive Seizures, ARS, Diazepam, Cluster Seizures
- Medical subject headings
- Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Intramuscular autoinjector; administered at onset of an episode
Vanquix Auto-Injector (Diazepam Injection)Drug
Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | During the Double-blind Period, participants received a single, age- and weight-appropriate dose of placebo solution as a deep intramuscular injection in the mid to outer thigh. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of acute repetitive seizures (ARS). Receives: Drug: Placebo |
| Diazepam | Experimental | During the Double-blind Period, participants received a single, age- and weight-appropriate dose of diazepam solution, ranging from 0.2 to 0.5 mg/kg, as a deep intramuscular injection in the mid to outer thigh. Additional doses were permissible during the Open-label Period. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of ARS. Receives: Drug: Vanquix Auto-Injector (Diazepam Injection) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to Next Seizure or Rescue Medication During the Double-blind Period (Kaplan-Meier 50th Percentile)
An event was defined as an episode of or required rescue medication for an episode of acute repetitive seizures (ARS) within 15 minutes to 12 hours following study drug administration. Patients without an ARS event were censored at 12 hours. Diaries were provided; if no diary was returned, or the diary did not provide answers to questions about seizures and rescue during the 12-hour follow-up period, the patient was considered censored as of 15 minutes past the treatment time, unless another contact was documented. If seizure control following study drug administration was inadequate, diazepam rectal gel was provided as a rescue medication, given only in the first 4 hours after study drug administration and only if the caregiver was directed to do so by the Investigator or designee at the time of the ARS episode. Patients and their caregivers were trained to recognize the onset of an episode of ARS and when and how to administer study drug.
Measured: From 15 minutes to 12 hours after study drug administration for an episode of ARS during the Double-blind Period
Percentage of Participants With an Event (Next Seizure or Rescue Medication) During the Open-label Period
An event was defined as an episode of or required rescue medication for an episode of acute repetitive seizures (ARS) within 15 minutes to 12 hours following study drug administration. Patients without an ARS event were censored at 12 hours. Diaries were provided; if no diary was returned, or the diary did not provide answers to questions about seizures and rescue during the 12-hour follow-up period, the patient was considered censored as of 15 minutes past the treatment time, unless another contact was documented. If seizure control following study drug administration was inadequate, diazepam rectal gel was provided as a rescue medication, given only in the first 4 hours after study drug administration and only if the caregiver was directed to do so by the Investigator or designee at the time of the ARS episode. Patients and their caregivers were trained to recognize the onset of an episode of ARS and when and how to administer study drug.
Measured: From 15 minutes to 12 hours after study drug administration for an episode of ARS during the Double-blind Period
Secondary outcomes (10)
Number of Participants Requiring Rescue Medication During the Double-blind Period
If seizure control following study drug administration was inadequate, diazepam rectal gel was provided as a rescue medication, given only in the first 4 hours after study drug administration and only if the caregiver was directed to do so by the Investigator or designee at the time of the acute repetitive seizure (ARS) episode. Each patient's specific criteria for seizure and an episode of ARS were determined by the Investigator. Patients and their caregivers were trained to use these criteria to recognize the onset of an episode of ARS and when and how to administer study drug. An episode of ARS was defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.
Measured: From 15 minutes to 12 hours following study drug administration for an episode of ARS during the Double-blind Period
Number of Participants Requiring Emergency Department Visits During the Double-blind Period
Any use of emergency treatment (such as an emergency room visit) was recorded in the patient's diary, along with the date, time, and reason for the emergency treatment. Emergency department visits required some type of rescue action taken, other than the visit itself. An episode of acute repetitive seizures (ARS) was defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.
Measured: From 15 minutes to 12 hours following study drug administration for onset of an episode of ARS during the Double-blind Period
Number of Participants Requiring Rescue Medical Care Other Than Rescue Medication or Emergency Department Visits During the Double-blind Period
Other rescue medical care consisted of care other than rescue medication or emergency department visits. Each patient's specific criteria for seizure and an episode of acute repetitive seizure (ARS) were determined by the Investigator. Patients and their caregivers were trained to use these criteria to recognize the onset of an episode of ARS and when and how to administer study drug. An episode of ARS was defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.
Measured: From 15 minutes to 12 hours following study drug administration for an episode of ARS during the Double-blind Period
Mean Score on Caregiver Global Treatment Assessment During the Double-blind Period
Caregiver global evaluation is based on seizure frequency, severity, and overall outcome compared with previous episodes and is rated on a 10-cm visual analogue scale, where 0=much worse and 10=much better. A higher score indicates greater improvement. An episode of acute repetitive seizures (ARS) is defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.
Measured: Assessments completed at the end of each treated episode of ARS in the Double-blind Period
Mean Score on Physician Global Treatment Assessment During the Double-blind Period
Physician global evaluation is based on seizure frequency, severity, and overall outcome compared with previous episodes. The physician global evaluation is rated on a 10-cm visual analogue scale, where 0=much worse and 10=much better. A higher score indicates greater improvement. An episode of acute repetitive seizures (ARS) was defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.
Measured: At Visit 2 and subsequent visits in the Double-blind Period
Number of Participants Requiring Rescue Medication During the Open-label Period
Each patient's specific criteria for seizure and an episode of acute repetitive seizure (ARS) were determined by the Investigator. Patients and their caregivers were trained to use these criteria to recognize the onset of an episode of ARS and when and how to administer study drug. If seizure control following study drug administration was inadequate, diazepam rectal gel was provided as a rescue medication, given only in the first 4 hours after study drug administration and only if the caregiver was directed to do so by the Investigator or designee at the time of the ARS episode.
Measured: From 15 minutes to 12 hours after study drug administration during the Open-label Period
Number of Participants Requiring Emergency Department Visits During the Open-label Period
Any use of emergency treatment (such as an emergency room visit) was recorded in the patient's diary, along with the date, time, and reason for the emergency treatment. Emergency department visits required some type of rescue action taken, other than the visit itself.
Measured: From 15 minutes to 12 hours after study drug administration for onset of an episode of ARS during the Open-label Period
Number of Participants Requiring Rescue Medical Care Other Than Medication or Emergency Department Visits During the Open-label Period
Other rescue medical care consisted of care other than rescue medication or emergency department visits. Each patient's specific criteria for seizure and an episode of acute repetitive seizure (ARS) were determined by the Investigator. Patients and their caregivers were trained to use these criteria to recognize the onset of an episode of ARS and when and how to administer study drug.
Measured: From 15 minutes to 12 hours after study drug administration for onset of an episode of ARS during the Open-label Period
Mean Score on Caregiver Global Treatment Assessment During the Open-label Period
Caregiver global evaluation is based on seizure frequency, severity, and overall outcome compared with previous episodes and is rated on a 10-cm visual analogue scale, where 0=much worse and 10=much better. A higher score indicates greater improvement. An episode of acute repetitive seizures (ARS) is defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.
Measured: Assessments completed at the end of each treated episode of ARS in the Open-label Period
Mean Score on Physician Global Treatment Assessment During the Open-label Period
Physician global evaluation is based on seizure frequency, severity, and overall outcome compared with previous episodes and is rated on a 10-cm visual analogue scale, where 0=much worse and 10=much better. A higher score indicates greater improvement. An episode of acute repetitive seizures (ARS) is defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.
Measured: From Visit 2 and subsequent visits in the Open-label Period to discharge or study termination
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Apr 2006 (estimated)
- Study startJan 2006
- Primary completionJul 2014
- Study completionJul 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SeizuresStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 234 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00319501
- Sponsor's protocol ID
- K826-05-3001
- Other IDs
- B4511001
- Status last verified
- Jul 2016
- First submitted
- 27 Apr 2006
- Last updated
- 23 Sep 2016
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Abou-Khalil B, Wheless J, Rogin J, Wolter KD, Pixton GC, Shukla RB, Sherman NA, Sommerville K, Goli V, Roland CL. A double-blind, randomized, placebo-controlled trial of a diazepam auto-injector administered by caregivers to patients with epilepsy who require intermittent intervention for acute repetitive seizures. Epilepsia. 2013 Nov;54(11):1968-76. doi: 10.1111/epi.12373. Epub 2013 Sep 20.
PubMed 24111974
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures
- ClinicalTrials.gov ID
- NCT00319501
- Acronym / sponsor ID
- K826-05-3001
- Keywords
- Acute Repetitive Seizures, ARS, Diazepam, Cluster Seizures
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 234 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Jan 2006
- Primary completion
- Jul 2014 (actual)
- Study completion
- Jul 2014 (actual)
- First posted
- 27 Apr 2006 (estimated)
- Results
- Posted 16 Aug 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the efficacy and safety of diazepam in the management of refractory epilepsy in selected patients who require intermittent medical intervention for the control of episodes of acute repetitive seizures. In addition, to assess the support provided by caregivers who are not themselves or not under the direct supervision of health care professionals at the time of administration.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboDuring the Double-blind Period, participants received a single, age- and weight-appropriate dose of placebo solution as a deep intramuscular injection in the mid to outer thigh. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of acute repetitive seizures (ARS). |
| Diazepam | Experimental | Drug: Vanquix Auto-Injector (Diazepam Injection)During the Double-blind Period, participants received a single, age- and weight-appropriate dose of diazepam solution, ranging from 0.2 to 0.5 mg/kg, as a deep intramuscular injection in the mid to outer thigh. Additional doses were permissible during the Open-label Period. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of ARS. |
Who may qualify
- Ages
- 2 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (14 listed)
- Older than 2 years of age and between 6 and 136 kg body weight
- Recipient of clinical diagnosis of epilepsy, taking a stable antiepileptic drug regimen for at least 2 weeks, and requiring intermittent medical intervention to control episodes of acute repetitive seizures (ARS)
- Experienced at least 2 episodes of ARS in previous year, one of which occurred in previous 6 months
- Has episodes of ARS that include complex partial or generalized seizures
- Has a responsible caregiver available to participate
Key exclusion criteria (9 listed)
- Petit mal status or petit mal variant status
- History of ARS consistently progressing to status epilepticus
- History of failure to respond to benzodiazepine treatment
- Hypersensitivity to diazepam
- Acute narrow angle glaucoma
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboIntramuscular autoinjector; administered at onset of an episode | Drug | Placebo |
| Vanquix Auto-Injector (Diazepam Injection)Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode | Drug | Diazepam |
Primary outcome
Time to Next Seizure or Rescue Medication During the Double-blind Period (Kaplan-Meier 50th Percentile)
Time frame: From 15 minutes to 12 hours after study drug administration for an episode of ARS during the Double-blind Period
An event was defined as an episode of or required rescue medication for an episode of acute repetitive seizures (ARS) within 15 minutes to 12 hours following study drug administration. Patients without an ARS event were censored at 12 hours. Diaries were provided; if no diary was returned, or the diary did not provide answers to questions about seizures and rescue during the 12-hour follow-up period, the patient was considered censored as of 15 minutes past the treatment time, unless another contact was documented. If seizure control following study drug administration was inadequate, diazepam rectal gel was provided as a rescue medication, given only in the first 4 hours after study drug administration and only if the caregiver was directed to do so by the Investigator or designee at the time of the ARS episode. Patients and their caregivers were trained to recognize the onset of an episode of ARS and when and how to administer study drug.
Percentage of Participants With an Event (Next Seizure or Rescue Medication) During the Open-label Period
Time frame: From 15 minutes to 12 hours after study drug administration for an episode of ARS during the Double-blind Period
An event was defined as an episode of or required rescue medication for an episode of acute repetitive seizures (ARS) within 15 minutes to 12 hours following study drug administration. Patients without an ARS event were censored at 12 hours. Diaries were provided; if no diary was returned, or the diary did not provide answers to questions about seizures and rescue during the 12-hour follow-up period, the patient was considered censored as of 15 minutes past the treatment time, unless another contact was documented. If seizure control following study drug administration was inadequate, diazepam rectal gel was provided as a rescue medication, given only in the first 4 hours after study drug administration and only if the caregiver was directed to do so by the Investigator or designee at the time of the ARS episode. Patients and their caregivers were trained to recognize the onset of an episode of ARS and when and how to administer study drug.
10 secondary outcomes
Number of Participants Requiring Rescue Medication During the Double-blind Period
Time frame: From 15 minutes to 12 hours following study drug administration for an episode of ARS during the Double-blind Period
Number of Participants Requiring Emergency Department Visits During the Double-blind Period
Time frame: From 15 minutes to 12 hours following study drug administration for onset of an episode of ARS during the Double-blind Period
Number of Participants Requiring Rescue Medical Care Other Than Rescue Medication or Emergency Department Visits During the Double-blind Period
Time frame: From 15 minutes to 12 hours following study drug administration for an episode of ARS during the Double-blind Period
Mean Score on Caregiver Global Treatment Assessment During the Double-blind Period
Time frame: Assessments completed at the end of each treated episode of ARS in the Double-blind Period
Mean Score on Physician Global Treatment Assessment During the Double-blind Period
Time frame: At Visit 2 and subsequent visits in the Double-blind Period
Number of Participants Requiring Rescue Medication During the Open-label Period
Time frame: From 15 minutes to 12 hours after study drug administration during the Open-label Period
Number of Participants Requiring Emergency Department Visits During the Open-label Period
Time frame: From 15 minutes to 12 hours after study drug administration for onset of an episode of ARS during the Open-label Period
Number of Participants Requiring Rescue Medical Care Other Than Medication or Emergency Department Visits During the Open-label Period
Time frame: From 15 minutes to 12 hours after study drug administration for onset of an episode of ARS during the Open-label Period
Mean Score on Caregiver Global Treatment Assessment During the Open-label Period
Time frame: Assessments completed at the end of each treated episode of ARS in the Open-label Period
Mean Score on Physician Global Treatment Assessment During the Open-label Period
Time frame: From Visit 2 and subsequent visits in the Open-label Period to discharge or study termination
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2016.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 24111974Abou-Khalil B, Wheless J, Rogin J, Wolter KD, Pixton GC, Shukla RB, Sherman NA, Sommerville K, Goli V, Roland CL. A double-blind, randomized, placebo-controlled trial of a diazepam auto-injector administered by caregivers to patients with epilepsy who require intermittent intervention for acute repetitive seizures. Epilepsia. 2013 Nov;54(11):1968-76. doi: 10.1111/epi.12373. Epub 2013 Sep 20.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Seizures
RecruitingPhase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Seizures, Lennox Gastaut Syndrome
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Focal Seizure, Epilepsy
RecruitingPhase 3
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Stereotypical Prolonged Seizures
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Focal Seizure, Epilepsy
Not yet recruitingPhase 4
Study of Electrocardiogram (ECG) Safety of Sezaby in Neonatal Seizures
Neonatal Seizure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
86 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Vanquix Auto-Injector (Diazepam Injection) in people with Seizures and Epilepsies, Partial, run by Pfizer at 86 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 86 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 16 Aug 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to Next Seizure or Rescue Medication During the Double-blind Period (Kaplan-Meier 50th Percentile) (time frame: From 15 minutes to 12 hours after study drug administration for an episode of ARS during the Double-blind Period). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00319501, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2016.